Intermediate‑Acting Insulin: Types, Action Profile, and Clinical Use

Intermediate‑acting insulins have onset ~1–2 hrs, peak 4–12 hrs, duration 12–18+ hrs. Used as basal component in split‑mixed regimens.

Types

  • NPH (Neutral Protamine Hagedorn): Human insulin + protamine + zinc → suspension. Cloudy. Must resuspend (roll/invert) before each dose. Peak ~4–10 hrs.
  • Lente (discontinued in US): Insulin + zinc (no protamine). Longer, flatter than NPH. Replaced by basal analogs.

Modern Context

  • Basal analogs (glargine U100/U300, detemir, degludec) have largely replaced NPH: flatter profile, less hypoglycemia, once‑daily (or q12h detemir), no resuspension.
  • NPH remains cost‑effective (vial ~$25 vs. $300+ for analogs) and is used in resource‑limited settings or mixed regimens.

Clinical Pearls

  • NPH given at bedtime covers overnight/dawn; morning dose covers afternoon.
  • Hypoglycemia risk highest at peak (night for bedtime dose).
  • Mixing: NPH + regular/rapid analog in same syringe (draw rapid first). Do not mix with other basal analogs.
  • Rotation of injection sites prevents lipohypertrophy (impairs absorption).

Individualize regimen with diabetes team. Time‑in‑range >70% is the goal.

Diabetes - Related Articles